




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8





FIG. 9






FIG. 11




FIG. 12




FIG. 14





FIG. 15






FIG. 16B




FIG. 16C




FIG. 17A




FIG. 17B




FIG. 18A




FIG. 18B




FIG. 19A




FIG. 19B




FIG. 20A




FIG. 20B




FIG. 21A




FIG. 21B




FIG. 22A




FIG. 22B




FIG. 23A




FIG. 23B




FIG. 24A




FIG. 24B

Lung Cancer Training Cohort		
Sample Group	<i>n</i>	Sample Source
Stage I and II LUAD/LUSqC	20/20	OTB, ProteoGenex iSpecimen
Stage III and IV LUAD/LUSqC	10/10	ProteoGenex
Healthy never-smoker	18	Mercy-Sponsored Collection
Healthy ever-smoker	30	Mercy-Sponsored Collection
COPD ever-smoker	10	ProteoGenex
Lung Cancer Validation Cohort		
Sample Group	<i>n</i>	Sample Source
Stage I and II LUAD/LUSqC	90/56	OTB
Stage III and IV LUAD/LUSqC	19/20	OTB
Healthy never-smoker	110	Mercy-Sponsored Collection
Healthy ever-smoker	117	Mercy-Sponsored Collection, ProteoGenex
COPD ever-smoker	44	ProteoGenex

FIG. 25




FIG. 26




FIG. 27

Cohort	<i>n</i>	Sensitivity at 80% Specificity (95% CI)
Stage I	71	62% (50%-73%)
Stage II	75	63% (51%-74%)
Stage III/IV	39	82% (66%-92%)

FIG. 28

Correlation with Model Output	Spearman Correlation	P-value
Tumor size	0.354	1.3e-7
Smoking history (healthy ever-smokers)	0.142	0.072

FIG. 29




FIG. 30

Screen-detected lung cancer cases		
Cohort	<i>n</i>	Sensitivity at 80% Specificity (95% CI)
Stage I	11	73% (39% - 64%)
Stage II	25	68% (46% - 85%)
Stage III/IV	6	83% (36% - 100%)

FIG. 31